Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

A New Look at an Old Disease: Recent Insights into the Global Epidemiology of Dengue.

Sharp TM, Tomashek KM, Read JS, Margolis HS, Waterman SH.

Curr Epidemiol Rep. 2017;4(1):11-21. doi: 10.1007/s40471-017-0095-y. Epub 2017 Jan 14. Review.

2.

Flavivirus-mosquito interactions.

Huang YJ, Higgs S, Horne KM, Vanlandingham DL.

Viruses. 2014 Nov 24;6(11):4703-30. doi: 10.3390/v6114703. Review.

3.

Flaviviruses, an expanding threat in public health: focus on dengue, West Nile, and Japanese encephalitis virus.

Daep CA, Muñoz-Jordán JL, Eugenin EA.

J Neurovirol. 2014 Dec;20(6):539-60. doi: 10.1007/s13365-014-0285-z. Epub 2014 Oct 7. Review.

4.

TNF-α promoter polymorphism: a factor contributing to the different immunological and clinical phenotypes in Japanese encephalitis.

Pujhari SK, Ratho RK, Prabhakar S, Mishra B, Modi M.

BMC Infect Dis. 2012 Jan 26;12:23. doi: 10.1186/1471-2334-12-23.

5.

Stability of yellow fever virus under recombinatory pressure as compared with chikungunya virus.

McGee CE, Tsetsarkin KA, Guy B, Lang J, Plante K, Vanlandingham DL, Higgs S.

PLoS One. 2011;6(8):e23247. doi: 10.1371/journal.pone.0023247. Epub 2011 Aug 3.

6.

Demographic and clinical features of dengue fever in Pakistan from 2003-2007: a retrospective cross-sectional study.

Khan E, Kisat M, Khan N, Nasir A, Ayub S, Hasan R.

PLoS One. 2010 Sep 13;5(9):e12505. doi: 10.1371/journal.pone.0012505.

7.

TRAIL is a novel antiviral protein against dengue virus.

Warke RV, Martin KJ, Giaya K, Shaw SK, Rothman AL, Bosch I.

J Virol. 2008 Jan;82(1):555-64. Epub 2007 Oct 3.

8.
9.

Activity of T-1106 in a hamster model of yellow Fever virus infection.

Julander JG, Furuta Y, Shafer K, Sidwell RW.

Antimicrob Agents Chemother. 2007 Jun;51(6):1962-6. Epub 2007 Apr 9.

10.

Travel medicine for the extreme traveler.

Boulware DR.

Dis Mon. 2006 Aug;52(8):309-25. Review. No abstract available.

Supplemental Content

Support Center